Bastiano Sanna - 18 Oct 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Cell & Genetic Therapies
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
18 Oct 2022
Net transactions value
-$537,860
Form type
4
Filing time
20 Oct 2022, 16:11:40 UTC
Previous filing
03 Aug 2022
Next filing
03 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale $450,930 -1,503 -3.7% $300.02 39,480 18 Oct 2022 Direct F1, F2, F3
transaction VRTX Common Stock Sale $86,930 -288 -0.73% $301.84 39,192 18 Oct 2022 Direct F1, F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1.
F2 Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $300.02 (range $300.00 to $300.14).
F4 Open market sales reported on this line occurred at a weighted average price of $301.84 (range $301.14 to $301.98).